Have your parents or grandparents ever had trouble driving, reading or recognizing faces? They might be suffering from age-related macular degeneration, a progressive disease afflicting about 11 ...

The Food and Drug Administration will allow a new device to be marketed as a treatment for dry age-related macular degeneration.

Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB ...

The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which the agency described as ...

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) application for HG202, the world's first ...

The drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related ...

You may have seen advertisements claiming to eliminate the need for eyeglasses through vision therapy or vision training – ...

HuidaGene Therapeutics gets US FDA clearance for CRISPR/Cas13 RNA-editing HG202 for macular degeneration: Shanghai Tuesday, November 5, 2024, 09:00 Hrs [IST] HuidaGene Therapeutic ...

Sight Care is an all-new vision support complex that has become a topic of discussion in the market over the past few ...

PulseSight plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its ...